A Phase 2 interventional study of Evobrutinib and Evobrutinib in Relapsing-remitting Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute, Inc.. Terminated at 56 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Merck KGaA, Darmstadt, Germany.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 35th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 200 across the 21 interventional studies, 150 across the 19 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under EMD Serono Research & Development Institute, Inc., one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono Research & Development Institute, Inc. is the lead sponsor of 87 studies on the registry; 8 are open to participants now.
Of its 47 completed or terminated interventional studies of FDA-regulated products, 38 (81%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis. Participants were placed into 1 of 3 groups to receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the participants on placebo were given M2951.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
Drug: Evobrutinib
Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 25 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Drug: Evobrutinib
Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Drug: Evobrutinib
Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Drug: Evobrutinib
Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period received Tecfidera 120 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Drug: Tecfidera
Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
Drug: Placebo
Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 mg orally, QD from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Drug: Evobrutinib
Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Also known as: M2951
Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 25 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Also known as: M2951
Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period received Evobrutinib 75 mg QD orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Also known as: M2951
Placebo were administered for 24 weeks in active treatment period.
Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period received Tecfidera 120 mg BID orally from Week 48 of BE period (OLE period Day 1) to Week 336 in OLE period.
Total Number of Gadolinium-Enhancing T1 Lesions
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 12 to Week 24
Annualized Relapse Rate (ARR) at Week 24
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 24
Qualified Relapse-Free Status at Week 24
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status at week 24 were reported. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 24
Change From Baseline in Expanded Disability Status Scale (EDSS) at Week 24
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS). As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Baseline, Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the date of first dose and within 28 days after the date of last dose in the study. TEAEs include both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Safety Follow-up (Week 52)
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs and Electrocardiograms (ECGs)
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Number of participants with clinically significant change from baseline in vital signs and ECG were reported. Clinical Significance was decided by the investigator.
Time frame: Baseline up to Safety Follow-up (Week 52)
Number of Participants With Grade 3 or Higher Hematology, Biochemistry and Urinalysis Values
Hematology, biochemistry, and urinalysis values were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grades (where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death). For the hematology and biochemistry parameters, participants with a value grade 3 or higher were reported. For the urinalysis parameters, participants with a value grade 3 or higher, or a value \>= 2 upper limit of normal (ULN), or a value classified as ++ Increasing were reported.
Time frame: Baseline up to Safety Follow-up (Week 52)
Absolute Concentrations of Immunoglobulin (Ig) Levels (Active Treatment Period)
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline (Day 1), Weeks 4, 16, and 24
Absolute Concentrations of Immunoglobulin (Ig) Levels (Blinded Extension Period)
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
Time frame: Week 48
Change From Baseline in Immunoglobulin (Ig) Levels (Active Treatment Period)
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline (Day 1), Weeks 4, 16, and 24
Change From Baseline in Immunoglobulin (Ig) Levels (Blinded Extension Period)
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline (Week 25), Week 48
Absolute Concentration of B Cells (Active Treatment Period)
Absolute concentration of B Cells are reported.
Time frame: Baseline (Day 1), Weeks 4, and 24
Absolute Concentration of B Cells (Blinded Extension Period)
Absolute concentration of B Cells were reported.
Time frame: Weeks 48 and 52
Change From Baseline in Absolute B Cells (Active Treatment Period)
Change from baseline in absolute B cells are reported.
Time frame: Baseline (Day 1), Weeks 4 and 24
Change From Baseline in Absolute B Cells (Blinded Extension Period)
Change from baseline in absolute B cells are reported.
Time frame: Baseline (Week 25), Weeks 48 and 52
Total Number of New Gadolinium-positive (Gd+) T1 Lesions
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 12 to 24
Mean Per-scan Number of Gadolinium-positive (Gd+) T1 Lesions
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 12 to Week 24
Total Number of New or Enlarging T2 Lesions
Analysis of New or Enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Week 12 to Week 24
Change From Baseline in Volume of T2 Lesions at Week 24
Analysis of volume of T2 lesions was done using magnetic resonance imaging (MRI) scans. Tecfidera treatment group was not included in inferential analysis.
Time frame: Baseline, Week 24
Change From Baseline in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 24
Analysis of volume of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
Time frame: Baseline, Week 24
Number of Gadolinium-positive (Gd+) T1 Lesions at Week 48
Analysis of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Week 48
Number of New Gadolinium-positive (Gd+) T1 Lesions at Week 48
Analysis of new Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Week 48
Annualized Relapse Rate (ARR)
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: Week 0 to Week 48
Qualified Relapse-free Status
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status were reported.
Time frame: Week 25 to Week 48
Change From Week 24 in Expanded Disability Status Scale (EDSS) at Week 48
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: Week 24, Week 48
Total Number of New or Enlarging T2 Lesions at Week 48 Relative to Week 24
Analysis of New or Enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Week 24 to Week 48
Change From Week 24 in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 48
Analysis of volume of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Week 24, Week 48
Change From Week 24 in Volume of T2 Lesions at Week 48
Analysis of volume of T2 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: Week 24, Week 48
OLE Period: Total Number of Gadolinium-Enhancing T1 Lesions
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: OLE Baseline (BE period Week 48), OLE Weeks 96, 144, 192, 240, 288 and 336
OLE Period: Annualized Relapse Rate (ARR)
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Time frame: OLE Baseline (BE period Week 48), OLE Weeks 96, 144, 192, 240, 288 and 336
OLE Period: Percentage of Participants With Qualified Relapse-Free Status
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status from OLE Baseline (BE period Week 48) up to Week 336 were reported.
Time frame: OLE Baseline (BE period Week 48) up to OLE Week 336
OLE Period: Change From Baseline in Expanded Disability Status Scale (EDSS) at Week 96, 144, 192, 240, 288 and 336
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
Time frame: OLE Baseline (BE period Week 48), OLE Weeks 96, 144, 192, 240, 288 and 336
OLE Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the date of first dose and within 28 days after the date of last dose in the study. TEAEs include both Serious TEAEs and non-serious TEAEs.
Time frame: OLE Baseline (BE period Week 48) up to OLE Week 336
OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Number of participants with clinically significant change from baseline in vital signs were reported. Clinical Significance was decided by the investigator.
Time frame: OLE Baseline (BE period Week 48) up to OLE Week 336
OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
Laboratory parameters included hematology, biochemistry, and urinalysis. Number of participants with clinically significant change from baseline in laboratory parameters were reported. Clinical Significance was decided by the investigator.
Time frame: OLE Baseline (BE period Week 48) up to OLE Week 336
OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECGs)
ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Number of participants with clinically significant change from baseline in ECG were reported. Clinical Significance was decided by the investigator.
Time frame: OLE Baseline (BE period Week 48) up to OLE Week 336
OLE Period: Absolute Concentrations of Immunoglobulin (Ig) Levels
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
Time frame: OLE Baseline (BE period Week 48), OLE Weeks 96, 144, 192, 240 and 288
OLE Period: Change From Baseline in Immunoglobulin (Ig) Levels
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
Time frame: OLE Baseline (BE period Week 48), OLE Weeks 96, 144, 192, 240 and 288
| Milestone | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|---|
| Started | 54 | 0 | 0 | 52 | 53 | 54 | 54 |
| Safety analysis set | 54 | 0 | 0 | 52 | 53 | 54 | 54 |
| Completed | 49 | 0 | 0 | 47 | 48 | 48 | 52 |
| Not completed | 5 | 0 | 0 | 5 | 5 | 6 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 2 | 2 | 6 | 2 |
| Milestone | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 49 | 0 | 47 | 48 | 48 | 52 |
| Completed | 0 | 42 | 0 | 43 | 44 | 46 | 52 |
| Not completed | 0 | 7 | 0 | 4 | 4 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 0 | 2 | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 39 | 39 | 42 | 44 | 49 |
| Completed | 0 | 0 | 28 | 25 | 33 | 35 | 39 |
| Not completed | 0 | 0 | 11 | 14 | 9 | 9 | 10 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 | 2 | 1 | 2 |
| Withdrew: Study reached its predefined end | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Covid-19 related | 0 | 0 | 0 | 1 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 3 | 3 | 1 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 7 | 2 | 4 | 2 |
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| Lesions | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Total Number of Gadolinium-Enhancing T1 Lesions | 3.85 ± 5.436 | 4.06 ± 8.024 | 1.69 ± 4.693 | 1.15 ± 3.702 | 4.78 ± 22.045 |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| relapses per year | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Annualized Relapse Rate (ARR) at Week 24 | 0.37 (0.17 to 0.70) | 0.57 (0.30 to 0.97) | 0.13 (0.03 to 0.38) | 0.08 (0.01 to 0.30) | 0.20 (0.06 to 0.47) |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status at week 24 were reported. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| percentage of participants | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Qualified Relapse-Free Status at Week 24 | 77.4 (63.8 to 87.7) | 74.0 (59.7 to 85.4) | 88.2 (76.1 to 95.6) | 86.8 (74.7 to 94.5) | 88.9 (77.4 to 95.8) |
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS). As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| Units on a scale | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Baseline in Expanded Disability Status Scale (EDSS) at Week 24 | -0.03 ± 0.301 | 0.02 ± 0.622 | -0.14 ± 0.664 | 0.04 ± 0.216 | 0.02 ± 0.274 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the date of first dose and within 28 days after the date of last dose in the study. TEAEs include both Serious TEAEs and non-serious TEAEs.
| Participants | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|
| TEAEs | 24 | 19 | 28 | 35 | 34 | 35 |
| Serious TEAEs | 2 | 0 | 2 | 2 | 4 | 2 |
| TEAEs Leading to Death | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Number of participants with clinically significant change from baseline in vital signs and ECG were reported. Clinical Significance was decided by the investigator.
| Participants | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|
| Vital Sign Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 |
| ECG Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 |
Hematology, biochemistry, and urinalysis values were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 toxicity grades (where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death). For the hematology and biochemistry parameters, participants with a value grade 3 or higher were reported. For the urinalysis parameters, participants with a value grade 3 or higher, or a value \>= 2 upper limit of normal (ULN), or a value classified as ++ Increasing were reported.
| Participants | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|---|
| Grade >= 3 hematology values | 0 | 2 | 0 | 1 | 0 | 1 |
| Grade >= 3 biochemistry values | 2 | 8 | 6 | 9 | 16 | 9 |
| Grade >= 3 or value >= 2 ULN or ++ Increasing urinalysis values | 0 | 2 | 1 | 2 | 2 | 6 |
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Ig A, Day 1 | 1.99 ± 0.777 | 1.89 ± 0.764 | 1.90 ± 0.722 | 1.87 ± 0.675 | 2.03 ± 0.763 |
| Ig A, Week 4 | 1.98 ± 0.777 | 1.92 ± 0.770 | 1.93 ± 0.762 | 1.94 ± 0.748 | 1.90 ± 0.699 |
| Ig A, Week 16 | 2.07 ± 0.824 | 2.10 ± 0.813 | 2.13 ± 0.832 | 2.08 ± 0.753 | 2.03 ± 0.752 |
| Ig A, Week 24 | 1.99 ± 0.807 | 2.12 ± 0.833 | 2.09 ± 0.838 | 2.09 ± 0.793 | 1.97 ± 0.757 |
| Ig G, Day 1 | 9.61 ± 1.897 | 9.43 ± 2.126 | 9.81 ± 1.841 | 9.62 ± 1.960 | 9.47 ± 1.839 |
| Ig G, Week 4 | 9.64 ± 2.094 | 9.34 ± 1.972 | 9.79 ± 1.910 | 9.64 ± 1.987 | 9.05 ± 1.922 |
| Ig G, Week 16 | 9.68 ± 2.085 | 9.41 ± 2.077 | 9.70 ± 1.991 | 9.56 ± 2.129 | 9.58 ± 1.850 |
| Ig G, Week 24 | 9.66 ± 2.081 | 9.46 ± 2.123 | 9.62 ± 2.048 | 9.36 ± 1.988 | 9.27 ± 1.866 |
| Ig M, Day 1 | 1.42 ± 0.692 | 1.27 ± 0.542 | 1.44 ± 0.716 | 1.33 ± 0.684 | 1.27 ± 0.589 |
| Ig M, Week 4 | 1.40 ± 0.668 | 1.21 ± 0.526 | 1.32 ± 0.654 | 1.28 ± 0.656 | 1.23 ± 0.603 |
| Ig M, Week 16 | 1.43 ± 0.703 | 1.13 ± 0.558 | 1.24 ± 0.639 | 1.20 ± 0.689 | 1.28 ± 0.678 |
| Ig M, Week 24 | 1.44 ± 0.748 | 1.03 ± 0.499 | 1.20 ± 0.672 | 1.08 ± 0.494 | 1.29 ± 0.667 |
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|
| IgA | 2.13 ± 0.807 | 2.18 ± 0.790 | 2.23 ± 0.838 | 2.06 ± 0.695 |
| IgG | 9.53 ± 2.070 | 9.74 ± 1.902 | 9.38 ± 2.189 | 9.60 ± 1.968 |
| IgM | 1.08 ± 0.557 | 1.13 ± 0.639 | 1.10 ± 0.692 | 1.28 ± 0.635 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Ig A, Week 4 | -0.02 ± 0.201 | 0.02 ± 0.165 | 0.04 ± 0.169 | 0.07 ± 0.195 | -0.13 ± 0.238 |
| Ig A, Week 16 | 0.10 ± 0.188 | 0.18 ± 0.245 | 0.21 ± 0.313 | 0.22 ± 0.209 | -0.02 ± 0.274 |
| Ig A, Week 24 | 0.06 ± 0.250 | 0.21 ± 0.283 | 0.18 ± 0.416 | 0.22 ± 0.229 | -0.06 ± 0.207 |
| Ig G, Week 4 | 0.02 ± 0.758 | -0.10 ± 0.697 | -0.02 ± 0.688 | 0.02 ± 0.581 | -0.42 ± 0.926 |
| Ig G, Week 16 | 0.04 ± 0.747 | -0.07 ± 0.964 | -0.10 ± 1.068 | -0.05 ± 0.710 | 0.07 ± 0.961 |
| Ig G, Week 24 | 0.06 ± 0.682 | 0.00 ± 1.228 | -0.15 ± 1.058 | -0.28 ± 0.774 | -0.23 ± 0.882 |
| Ig M, Week 4 | -0.01 ± 0.210 | -0.06 ± 0.100 | -0.12 ± 0.233 | -0.05 ± 0.133 | -0.04 ± 0.132 |
| Ig M, Week 16 | 0.02 ± 0.177 | -0.12 ± 0.184 | -0.18 ± 0.244 | -0.14 ± 0.189 | -0.00 ± 0.184 |
| Ig M, Week 24 | 0.04 ± 0.163 | -0.14 ± 0.286 | -0.20 ± 0.289 | -0.21 ± 0.167 | -0.00 ± 0.186 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|
| IgA | 0.26 ± 0.248 | 0.28 ± 0.275 | 0.36 ± 0.320 | 0.03 ± 0.316 |
| IgG | 0.11 ± 1.024 | -0.08 ± 0.940 | -0.24 ± 0.883 | 0.10 ± 1.244 |
| IgM | -0.18 ± 0.211 | -0.27 ± 0.287 | -0.23 ± 0.218 | -0.01 ± 0.198 |
Absolute concentration of B Cells are reported.
| cells per micro-liter | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Day 1 | 242 ± 134.2 | 208 ± 117.5 | 247 ± 131.8 | 219 ± 113.7 | 210 ± 97.4 |
| Week 4 | 243 ± 130.8 | 220 ± 92.7 | 277 ± 156.2 | 270 ± 143.2 | 201 ± 114.3 |
| Week 24 | 264 ± 154.9 | 230 ± 119.7 | 235 ± 115.3 | 214 ± 105.0 | 180 ± 114.3 |
Absolute concentration of B Cells were reported.
| cells per micro-liter | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|
| Week 48 | 203 ± 111.9 | 222 ± 148.8 | 187 ± 87.1 | 181 ± 109.8 |
| Week 52 | 227 ± 93.7 | 206 ± 140.3 | 154 ± 73.6 | 135 ± 29.0 |
Change from baseline in absolute B cells are reported.
| cells per micro-liter | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Week 4 | -5 ± 94.5 | 9 ± 112.2 | 31 ± 114.2 | 50 ± 86.7 | -3 ± 111.0 |
| Week 24 | 7 ± 135.8 | 13 ± 98.2 | -15 ± 128.5 | -9 ± 85.1 | -26 ± 113.9 |
Change from baseline in absolute B cells are reported.
| cells per micro-liter | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|
| Week 48 | -5 ± 116.1 | -30 ± 148.2 | -32 ± 97.9 | -15 ± 105.7 |
| Week 52 | -28 ± 209.8 | -25 ± 65.5 | -81 ± 119.0 | 15 ± 22.6 |
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| Lesions | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Total Number of New Gadolinium-positive (Gd+) T1 Lesions | 3.08 ± 4.371 | 3.44 ± 6.846 | 1.20 ± 3.499 | 0.98 ± 3.273 | 3.24 ± 15.320 |
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| Lesions | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Mean Per-scan Number of Gadolinium-positive (Gd+) T1 Lesions | 1.02 ± 1.439 | 1.31 ± 3.130 | 0.42 ± 1.173 | 0.34 ± 0.960 | 1.45 ± 7.293 |
Analysis of New or Enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| Lesions | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Total Number of New or Enlarging T2 Lesions | 5.96 ± 6.994 | 6.52 ± 11.569 | 3.41 ± 10.752 | 2.19 ± 4.719 | 5.35 ± 16.667 |
Analysis of volume of T2 lesions was done using magnetic resonance imaging (MRI) scans. Tecfidera treatment group was not included in inferential analysis.
| cubic centimeter (cc) | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Baseline in Volume of T2 Lesions at Week 24 | 0.42 ± 1.009 | 0.93 ± 1.853 | -0.01 ± 0.562 | 0.09 ± 0.463 | 0.47 ± 2.964 |
Analysis of volume of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans. As per planned analysis, Tecfidera treatment group was not included in inferential analysis.
| cc | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Baseline in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 24 | -0.023 ± 0.2220 | 0.057 ± 0.3479 | -0.111 ± 0.5416 | -0.051 ± 0.1032 | -0.050 ± 0.4771 |
Analysis of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
| Lesions | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Number of Gadolinium-positive (Gd+) T1 Lesions at Week 48 | 1.00 ± 1.614 | 1.91 ± 4.296 | 0.85 ± 2.867 | 0.49 ± 1.218 | 0.42 ± 1.444 |
Analysis of new Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
| Lesions | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Number of New Gadolinium-positive (Gd+) T1 Lesions at Week 48 | 0.95 ± 1.569 | 1.84 ± 4.154 | 0.85 ± 2.867 | 0.49 ± 1.218 | 0.42 ± 1.444 |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| relapses per year | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Annualized Relapse Rate (ARR) | 0.37 (0.21 to 0.59) | 0.52 (0.33 to 0.78) | 0.25 (0.12 to 0.44) | 0.11 (0.04 to 0.25) | 0.14 (0.06 to 0.29) |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status were reported.
| percentage of participants | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Qualified Relapse-free Status | 84.1 | 86.4 | 78.3 | 91.1 | 96.0 |
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
| Units on a scale | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Week 24 in Expanded Disability Status Scale (EDSS) at Week 48 | -0.05 ± 0.260 | -0.10 ± 0.351 | -0.01 ± 0.619 | 0.00 ± 0.238 | -0.10 ± 0.404 |
Analysis of New or Enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans.
| Lesions | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Total Number of New or Enlarging T2 Lesions at Week 48 Relative to Week 24 | 3.57 ± 4.346 | 5.86 ± 11.330 | 3.84 ± 10.083 | 1.60 ± 3.799 | 1.88 ± 4.796 |
Analysis of volume of Gd+ T1 lesions was done using magnetic resonance imaging (MRI) scans.
| cc | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Week 24 in Volume of Gadolinium-positive (Gd+) T1 Lesions at Week 48 | 0.092 ± 0.4626 | 0.088 ± 0.4006 | 0.045 ± 0.2285 | 0.024 ± 0.1981 | -0.203 ± 1.1073 |
Analysis of volume of T2 lesions was done using magnetic resonance imaging (MRI) scans.
| cc | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Change From Week 24 in Volume of T2 Lesions at Week 48 | 0.53 ± 1.360 | 0.67 ± 1.865 | 0.35 ± 1.083 | -0.03 ± 1.031 | -0.57 ± 2.699 |
Analysis of T1-Gadolinium enhancing lesions was done using magnetic resonance imaging (MRI) scans.
| Lesions | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Baseline (BE period Week 48) | 0.82 ± 2.668 | 1.74 ± 4.395 | 1.46 ± 4.519 | 1.16 ± 3.050 | 2.03 ± 11.829 |
| Week 96 | 0.13 ± 0.341 | 0.63 ± 1.822 | 0.49 ± 1.121 | 0.69 ± 1.411 | 0.67 ± 2.255 |
| Week 144 | 0.76 ± 2.294 | 0.41 ± 1.217 | 0.82 ± 3.512 | 0.54 ± 1.146 | 1.29 ± 5.940 |
| Week 192 | 1.00 ± 3.367 | 0.64 ± 1.890 | 0.81 ± 2.206 | 0.84 ± 1.798 | 0.96 ± 3.130 |
| Week 240 | 1.68 ± 5.800 | 0.63 ± 1.996 | 0.37 ± 1.189 | 0.77 ± 2.417 | 0.88 ± 3.204 |
| Week 288 | 0.35 ± 0.671 | 0.35 ± 0.786 | 0.32 ± 1.090 | 1.04 ± 2.946 | 0.35 ± 1.265 |
| Week 336 | 0.83 ± 1.602 | 3.00 ± 5.745 | 1.17 ± 2.858 | 0.29 ± 0.756 | 5.60 ± 18.310 |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
| relapses per year | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Baseline (BE period Week 48) | 0.29 (0.14 to 0.53) | 0.18 (0.06 to 0.38) | 0.14 (0.04 to 0.32) | 0.17 (0.07 to 0.36) | 0.12 (0.04 to 0.28) |
| Week 96 | 0.16 (0.05 to 0.37) | 0.13 (0.04 to 0.34) | 0.09 (0.02 to 0.26) | 0.08 (0.02 to 0.22) | 0.03 (0.00 to 0.16) |
| Week 144 | 0.07 (0.01 to 0.25) | 0.11 (0.02 to 0.33) | 0.03 (0.00 to 0.17) | 0.15 (0.05 to 0.34) | 0.16 (0.05 to 0.37) |
| Week 192 | 0.04 (0.00 to 0.20) | 0.08 (0.01 to 0.29) | 0.22 (0.09 to 0.45) | 0.16 (0.05 to 0.38) | 0.04 (0.00 to 0.20) |
| Week 240 | 0.16 (0.04 to 0.41) | 0.04 (0.00 to 0.23) | 0.10 (0.02 to 0.28) | 0.13 (0.04 to 0.34) | 0.00 (NA to 0.15) |
| Week 288 | 0.13 (0.13 to 0.38) | 0.05 (0.00 to 0.25) | 0.07 (0.01 to 0.25) | 0.00 (NA to 0.13) | 0.04 (0.00 to 0.24) |
| Week 336 | 0.00 (NA to 1.75) | 0.00 (NA to 1.55) | 0.31 (0.01 to 1.70) | 0.00 (NA to 1.27) | 0.00 (NA to 7.97) |
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of participants with qualified relapse-free status from OLE Baseline (BE period Week 48) up to Week 336 were reported.
| percentage of participants | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Period: Percentage of Participants With Qualified Relapse-Free Status | 66.7 | 68.4 | 71.4 | 65.9 | 83.3 |
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS).
| units on a scale | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Baseline (BE period Week 48) | 0.1 ± 0.39 | 0.0 ± 0.69 | 0.1 ± 0.46 | 0.0 ± 0.27 | 0.0 ± 0.34 |
| Week 96 | 0.1 ± 0.40 | 0.1 ± 0.46 | 0.2 ± 0.71 | 0.0 ± 0.42 | 0.0 ± 0.32 |
| Week 144 | 0.1 ± 0.79 | 0.1 ± 0.61 | 0.2 ± 0.79 | 0.0 ± 0.44 | 0.0 ± 0.28 |
| Week 192 | 0.2 ± 0.64 | 0.1 ± 0.61 | 0.2 ± 0.35 | 0.2 ± 0.72 | 0.0 ± 0.29 |
| Week 240 | 0.3 ± 0.72 | 0.3 ± 0.50 | 0.2 ± 0.46 | 0.2 ± 0.93 | 0.1 ± 0.40 |
| Week 288 | 0.4 ± 0.80 | 0.1 ± 0.87 | 0.4 ± 0.58 | 0.4 ± 0.81 | 0.2 ± 0.45 |
| Week 336 | 0.0 ± 0.52 | 0.5 ± 1.36 | 0.7 ± 1.38 | -0.2 ± 0.57 | 0.0 ± 0.52 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the date of first dose and within 28 days after the date of last dose in the study. TEAEs include both Serious TEAEs and non-serious TEAEs.
| Participants | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 35 | 29 | 41 | 40 | 37 |
Vital signs, including semi supine blood pressure, pulse rate, respiratory rate, weight, and oral temperature were assessed. Number of participants with clinically significant change from baseline in vital signs were reported. Clinical Significance was decided by the investigator.
| Participants | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Vital Signs | 0 | 0 | 0 | 0 | 0 |
Laboratory parameters included hematology, biochemistry, and urinalysis. Number of participants with clinically significant change from baseline in laboratory parameters were reported. Clinical Significance was decided by the investigator.
| Participants | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters | 0 | 0 | 0 | 0 | 0 |
ECG parameters included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Number of participants with clinically significant change from baseline in ECG were reported. Clinical Significance was decided by the investigator.
| Participants | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| OLE Period: Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECGs) | 0 | 0 | 0 | 0 | 0 |
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Ig A, OLE Baseline (BE period Week 48) | 2.31 ± 0.966 | 2.44 ± 0.897 | 2.49 ± 0.953 | 2.52 ± 0.970 | 2.31 ± 0.906 |
| Ig A, Week 72 | 2.38 ± 1.084 | 2.53 ± 1.075 | 2.72 ± 1.137 | 2.65 ± 1.062 | 2.43 ± 0.865 |
| Ig A, Week 96 | 2.42 ± 1.173 | 2.69 ± 1.026 | 2.91 ± 1.181 | 2.82 ± 1.113 | 2.62 ± 1.072 |
| Ig A, Week 144 | 2.57 ± 1.274 | 2.73 ± 0.918 | 2.82 ± 1.326 | 2.91 ± 1.233 | 2.57 ± 1.025 |
| IgA, Week 192 | 2.60 ± 1.242 | 2.71 ± 0.987 | 2.86 ± 1.255 | 3.15 ± 1.185 | 2.70 ± 1.055 |
| IgA, Week 240 | 2.71 ± 1.280 | 2.85 ± 1.095 | 3.05 ± 1.314 | 3.13 ± 1.269 | 2.65 ± 0.984 |
| IgA, Week 288 | 2.68 ± 1.305 | 3.08 ± 1.276 | 3.12 ± 1.306 | 3.30 ± 1.347 | 2.92 ± 1.108 |
| Ig G, OLE Baseline (BE period Week 48) | 9.75 ± 2.253 | 10.37 ± 2.512 | 10.73 ± 2.479 | 10.44 ± 2.291 | 9.65 ± 2.165 |
| Ig G, Week 72 | 9.63 ± 2.335 | 10.47 ± 2.509 | 10.69 ± 2.515 | 10.42 ± 2.116 | 9.93 ± 2.131 |
| Ig G, Week 96 | 9.46 ± 2.490 | 10.10 ± 2.461 | 10.76 ± 2.413 | 10.29 ± 2.172 | 9.93 ± 2.285 |
| Ig G, Week 144 | 9.48 ± 2.294 | 10.43 ± 2.304 | 10.38 ± 2.638 | 10.21 ± 2.552 | 9.32 ± 2.115 |
| IgG, Week 192 | 9.37 ± 2.156 | 9.99 ± 2.197 | 10.36 ± 2.548 | 10.46 ± 2.135 | 9.56 ± 2.094 |
| IgG, Week 240 | 9.28 ± 2.081 | 10.33 ± 2.422 | 10.47 ± 2.562 | 10.47 ± 2.562 | 9.58 ± 2.245 |
| IgG, Week 288 | 9.46 ± 2.068 | 10.48 ± 2.541 | 10.64 ± 2.566 | 10.36 ± 2.273 | 9.72 ± 2.700 |
| Ig M, OLE Baseline (BE period Week 48) | 1.06 ± 0.550 | 0.89 ± 0.403 | 1.08 ± 0.680 | 0.92 ± 0.422 | 0.99 ± 0.586 |
| Ig M, Week 72 | 1.03 ± 0.551 | 0.87 ± 0.397 | 1.05 ± 0.758 | 0.91 ± 0.425 | 0.94 ± 0.561 |
| Ig M, Week 96 | 1.01 ± 0.556 | 0.87 ± 0.413 | 1.05 ± 0.747 | 0.92 ± 0.460 | 0.91 ± 0.525 |
| Ig M, Week 144 | 0.88 ± 0.463 | 0.88 ± 0.468 | 0.94 ± 0.614 | 0.89 ± 0.377 | 0.90 ± 0.519 |
| Ig M, Week 192 | 0.89 ± 0.492 | 0.87 ± 0.461 | 0.90 ± 0.462 | 0.84 ± 0.320 | 0.90 ± 0.585 |
| Ig M, Week 240 | 0.85 ± 0.420 | 0.83 ± 0.419 | 0.87 ± 0.468 | 0.88 ± 0.369 | 0.87 ± 0.611 |
| Ig M, Week 288 | 0.85 ± 0.405 | 0.90 ± 0.490 | 0.94 ± 0.544 | 0.87 ± 0.397 | 1.03 ± 0.568 |
Change from baseline in the serum levels of IgG, IgA, IgM were assessed.
| Gram per Liter | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) |
|---|---|---|---|---|---|
| Ig A, OLE Baseline (BE period Week 48) | 0.26 ± 0.237 | 0.17 ± 0.333 | 0.19 ± 0.283 | 0.26 ± 0.291 | 0.28 ± 0.355 |
| Ig A, Week 72 | 0.40 ± 0.398 | 0.36 ± 0.515 | 0.41 ± 0.417 | 0.38 ± 0.453 | 0.42 ± 0.368 |
| Ig A, Week 96 | 0.44 ± 0.491 | 0.45 ± 0.407 | 0.58 ± 0.485 | 0.54 ± 0.446 | 0.59 ± 0.545 |
| Ig A, Week 144 | 0.58 ± 0.594 | 0.41 ± 0.347 | 0.50 ± 0.670 | 0.57 ± 0.589 | 0.54 ± 0.452 |
| IgA, Week 192 | 0.60 ± 0.597 | 0.38 ± 0.443 | 0.55 ± 0.667 | 0.82 ± 0.530 | 0.67 ± 0.492 |
| IgA, Week 240 | 0.67 ± 0.605 | 0.55 ± 0.471 | 0.74 ± 0.682 | 0.78 ± 0.621 | 0.68 ± 0.520 |
| IgA, Week 288 | 0.68 ± 0.934 | 0.75 ± 0.680 | 0.91 ± 0.915 | 1.02 ± 0.637 | 0.93 ± 0.724 |
| Ig G, OLE Baseline (BE period Week 48) | 0.39 ± 0.960 | 0.54 ± 1.463 | 0.69 ± 1.147 | 1.11 ± 1.150 | 0.23 ± 1.216 |
| Ig G, Week 72 | 0.40 ± 1.019 | 0.56 ± 1.364 | 0.79 ± 1.236 | 1.07 ± 0.994 | 0.48 ± 1.288 |
| Ig G, Week 96 | 0.17 ± 1.359 | 0.18 ± 1.228 | 0.64 ± 1.178 | 0.84 ± 1.073 | 0.47 ± 1.355 |
| Ig G, Week 144 | 0.35 ± 1.367 | 0.17 ± 1.451 | 0.31 ± 1.356 | 0.68 ± 1.458 | -0.09 ± 1.176 |
| IgG, Week 192 | 0.14 ± 1.227 | -0.13 ± 1.141 | 0.18 ± 1.625 | 0.84 ± 1.384 | 0.09 ± 1.324 |
| IgG, Week 240 | -0.01 ± 1.336 | 0.10 ± 1.557 | 0.37 ± 1.596 | 0.75 ± 1.362 | 0.19 ± 1.314 |
| IgG, Week 288 | 0.18 ± 1.492 | 0.48 ± 1.465 | 0.37 ± 2.203 | 1.01 ± 1.570 | 0.36 ± 1.440 |
| Ig M, OLE Baseline (BE period Week 48) | -0.18 ± 0.152 | -0.10 ± 0.120 | -0.09 ± 0.122 | -0.05 ± 0.099 | -0.28 ± 0.280 |
| IgM, Week 72 | -0.19 ± 0.170 | -0.11 ± 0.119 | -0.10 ± 0.147 | -0.07 ± 0.104 | -0.34 ± 0.264 |
| IgM, Week 96 | -0.23 ± 0.146 | -0.13 ± 0.141 | -0.09 ± 0.199 | -0.08 ± 0.127 | -0.35 ± 0.301 |
| IgM, Week 144 | -0.28 ± 0.323 | -0.14 ± 0.195 | -0.17 ± 0.174 | -0.11 ± 0.149 | -0.40 ± 0.327 |
| IgM, Week 192 | -0.28 ± 0.254 | -0.16 ± 0.204 | -0.19 ± 0.186 | -0.18 ± 0.197 | -0.46 ± 0.330 |
| IgM, Week 240 | -0.29 ± 0.282 | -0.20 ± 0.187 | -0.19 ± 0.205 | -0.16 ± 0.254 | -0.53 ± 0.348 |
| IgM, Week 288 | -0.29 ± 0.284 | -0.11 ± 0.313 | -0.15 ± 0.315 | -0.17 ± 0.178 | -0.39 ± 0.472 |
Collected over Baseline up to Safety Follow up of blinded extension period (Week 52); OLE Baseline (BE period Week 48) up to OLE Week 336. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Period 1) | 0/54 (0%) | 2/54 (3.7%) | 14/54 (25.9%) |
| Placebo Then Evobrutinib 25 mg QD (Period 2) | 0/49 (0%) | 0/49 (0%) | 9/49 (18.4%) |
| Evobrutinib 25 mg QD (Period 1 and Period 2) | 0/52 (0%) | 2/52 (3.8%) | 19/52 (36.5%) |
| Evobrutinib 75 mg QD (Period 1 and Period 2) | 0/53 (0%) | 2/53 (3.8%) | 19/53 (35.8%) |
| Evobrutinib 75 mg BID (Period 1 and Period 2) | 0/54 (0%) | 4/54 (7.4%) | 20/54 (37%) |
| Tecfidera (Period 1 and Period 2) | 0/54 (0%) | 2/54 (3.7%) | 30/54 (55.6%) |
| Placebo + Evobrutinib 25 mg QD (Period 3) | 0/39 (0%) | 7/39 (17.9%) | 30/39 (76.9%) |
| Evobrutinib 25 mg QD (Period 3) | 1/39 (2.6%) | 12/39 (30.8%) | 26/39 (66.7%) |
| Evobrutinib 75 mg QD (Period 3) | 0/42 (0%) | 8/42 (19%) | 34/42 (81%) |
| Evobrutinib 75 mg BID (Period 3) | 1/44 (2.3%) | 5/44 (11.4%) | 31/44 (70.5%) |
| Tecfidera (Period 3) | 1/49 (2%) | 10/49 (20.4%) | 26/49 (53.1%) |
| Event | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1 and Period 2) | Evobrutinib 75 mg QD (Period 1 and Period 2) | Evobrutinib 75 mg BID (Period 1 and Period 2) | Tecfidera (Period 1 and Period 2) | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 3) | Evobrutinib 75 mg QD (Period 3) | Evobrutinib 75 mg BID (Period 3) | Tecfidera (Period 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 2/39 | 0/42 | 0/44 | 0/49 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 0/39 | 2/42 | 0/44 | 0/49 |
| COVID-19 pneumoniaInfections and infestations | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 1/39 | 0/42 | 0/44 | 2/49 |
| Restless legs syndromeNervous system disorders | 0/54 | 0/49 | 0/52 | 0/53 | 1/54 | 0/54 | 1/39 | 0/39 | 0/42 | 0/44 | 0/49 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/54 | 0/49 | 0/52 | 1/53 | 0/54 | 0/54 | 0/39 | 1/39 | 0/42 | 0/44 | 0/49 |
| Microcytic anaemiaBlood and lymphatic system disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 1/39 | 0/42 | 0/44 | 0/49 |
| Myocardial ischaemiaCardiac disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 1/39 | 0/39 | 0/42 | 0/44 | 0/49 |
| Sinus tachycardiaCardiac disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 1/39 | 0/42 | 0/44 | 0/49 |
| Supraventricular tachycardiaCardiac disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 1/39 | 0/42 | 0/44 | 0/49 |
| CholelithiasisHepatobiliary disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 0/39 | 1/39 | 1/42 | 0/44 | 1/49 |
| Event | Placebo (Period 1) | Placebo Then Evobrutinib 25 mg QD (Period 2) | Evobrutinib 25 mg QD (Period 1 and Period 2) | Evobrutinib 75 mg QD (Period 1 and Period 2) | Evobrutinib 75 mg BID (Period 1 and Period 2) | Tecfidera (Period 1 and Period 2) | Placebo + Evobrutinib 25 mg QD (Period 3) | Evobrutinib 25 mg QD (Period 3) | Evobrutinib 75 mg QD (Period 3) | Evobrutinib 75 mg BID (Period 3) | Tecfidera (Period 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FlushingVascular disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 12/54 | 0/39 | 0/39 | 0/42 | 0/44 | 0/49 |
| Back painMusculoskeletal and connective tissue disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 1/39 | 5/39 | 9/42 | 3/44 | 0/49 |
| COVID-19Infections and infestations | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 0/54 | 6/39 | 8/39 | 3/42 | 6/44 | 7/49 |
| NasopharyngitisInfections and infestations | 5/54 | 1/49 | 9/52 | 3/53 | 7/54 | 2/54 | 7/39 | 7/39 | 8/42 | 9/44 | 4/49 |
| Lipase increasedInvestigations | 2/54 | 3/49 | 2/52 | 5/53 | 5/54 | 3/54 | 5/39 | 6/39 | 6/42 | 8/44 | 5/49 |
| Urinary tract infectionInfections and infestations | 3/54 | 0/49 | 2/52 | 1/53 | 0/54 | 0/54 | 7/39 | 5/39 | 7/42 | 5/44 | 3/49 |
| Upper respiratory tract infectionInfections and infestations | 0/54 | 0/49 | 1/52 | 1/53 | 1/54 | 3/54 | 5/39 | 2/39 | 6/42 | 4/44 | 3/49 |
| HeadacheNervous system disorders | 2/54 | 0/49 | 3/52 | 2/53 | 1/54 | 1/54 | 3/39 | 2/39 | 5/42 | 6/44 | 4/49 |
| ErythemaSkin and subcutaneous tissue disorders | 0/54 | 0/49 | 0/52 | 0/53 | 0/54 | 7/54 | 0/39 | 0/39 | 0/42 | 0/44 | 0/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/54 | 0/49 | 2/52 | 3/53 | 0/54 | 4/54 | 5/39 | 3/39 | 1/42 | 2/44 | 2/49 |
Modified Intent-To-Treat (mITT) analysis set included participants who belong to both Intent To Treat (ITT, consisted all participants who randomly allocated to a treatment, based on the intention to treat "as randomized" principle) and safety analysis sets (consisted all participants who receive at least 1 dose of trial treatment), and who have at least one baseline and one post-baseline magnetic resonance imaging (MRI) assessment.
| Age, Continuous(Years) | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) | Total |
|---|---|---|---|---|---|---|
| Mean | 41.6 ± 10.77 | 42.4 ± 9.37 | 42.9 ± 10.07 | 42.2 ± 11.50 | 42.8 ± 11.70 | 42.4 ± 10.67 |
| Sex: Female, Male(Participants) | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) | Total |
|---|---|---|---|---|---|---|
| Female | 39 | 32 | 35 | 36 | 39 | 181 |
| Male | 14 | 18 | 16 | 17 | 15 | 80 |
| Ethnicity (NIH/OMB)(Participants) | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 0 | 1 | 2 | 5 |
| Not Hispanic or Latino | 52 | 49 | 51 | 52 | 52 | 256 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo (Period 1) | Evobrutinib 25 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg QD (Period 1, 2 and 3) | Evobrutinib 75 mg BID (Period 1, 2 and 3) | Tecfidera (Period 1, 2 and 3) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 53 | 50 | 51 | 53 | 54 | 261 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Per company policy and with respect to the principles set forth by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the Declaration of Helsinki, and applicable laws and regulations , we inform the public about the designs and results of our clinical trials in a timely and balanced manner, regardless of the outcome. We are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with: safeguarding the privacy of patients; respecting the integrity of national regulatory systems; and maintaining incentives for investment in biomedical research.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Within six months after the occurrence of an approval of a new product or a new indication for an approved product in both the European Union and the United States after January 1, 2014 If approval of a product is not sought, Merck shall make publicly available such data within eighteen months after the trial completion date. Data will not be shared for products and indications approved prior to January 1, 2014
Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researcher qualifications and legitimacy of the research purpose.
Data sharing details ↗ · www.emdgroup.com
Ran from Mar 2017 to primary completion in Jan 2018, 10 months.
Results were first posted in Feb 2021, 3 years after primary completion. A results delay was requested in Jan 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Multiple Sclerosis, Relapsing-Remitting →
EMD Serono Research & Development Institute, Inc. →